Income Statement (TTM)
MYND Life Sciences Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2022 07-31 |
2024 07-31 |
|
|---|---|---|
| Revenue | -0 | 0 |
| Change (%) | -100.00 | |
| % of Revenue | 100.00 | 100.00 |
| Cost Of Sales | 0 | 0 |
| Change (%) | 98.60 | |
| % of Revenue | -363.66 | 33,177,900.00 |
| Gross Operating Profit | -0 | -0 |
| Change (%) | 55.77 | |
| % of Revenue | 463.66 | -33,177,800.00 |
| SG&A | 2 | 1 |
| Change (%) | -73.16 | |
| % of Revenue | -5,015.18 | 61,842,000.00 |
| R&D | 1 | 0 |
| Change (%) | -77.09 | |
| % of Revenue | -3,169.26 | 33,350,200.00 |
| OpEx | 4 | 1 |
| Change (%) | -67.89 | |
| % of Revenue | -8,718.19 | 128,598,100.00 |
| Operating Income | -4 | -1 |
| Change (%) | -68.25 | |
| % of Revenue | 8,818.19 | -128,598,000.00 |
| Interest Expense | -1 | -0 |
| Change (%) | -59.17 | |
| % of Revenue | 1,253.31 | -23,508,300.00 |
| Net Income | -7 | -1 |
| Change (%) | -91.78 | |
| % of Revenue | 14,375.75 | -54,256,500.00 |
Source: Capital IQ
